WASHINGTON, DC, May 18, 2020: Morgan Lewis is representing Metuchen Pharmaceuticals LLC in the company’s definitive agreement to merge with Neurotrope Inc. Under the terms of the agreement, the all-stock transaction will result in a newly formed holding company to be renamed Petros Pharmaceuticals Inc. that will focus on men’s health conditions.
Metuchen is a privately held biopharmaceutical company focused on identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health conditions. Neurotrope is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.
Partner Andrew Ray, associate Andrew Arthur, and of counsel Jeffrey Letalien represented Metuchen.